EGFR and non-small cell lung carcinoma: In EGFRmut NSCLC, tyrosine kinase inhibitors (TKIs) of EGFR have shown response rates of ~40–70%, with dramatic improvements in progression-free survival (PFS) in metastatic EGFRmut NSCLC patients compared to cytotoxic chemotherapy3.